SCHEMBL1124325

SCHEMBL1124325

Cc1ccc(/C=C/C(N)=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.62
FOS P01100 1/20 0.58
JUN P05412 1/20 0.58
ALDH1A1 P00352 1/20 0.56
CYP3A4 P08684 1/20 0.56
HPGD P15428 1/20 0.56
RAB9A P51151 5/20 0.55
MAOA P21397 3/20 0.55
MAOB P27338 3/20 0.55
KMT2A Q03164 2/20 0.55
POLB P06746 2/20 0.55
CYP1B1 Q16678 2/20 0.52
DDAH1 O94760 1/20 0.52
SLC5A1 P13866 1/20 0.51
SLC5A2 P31639 1/20 0.51
TRPM8 Q7Z2W7 1/20 0.51
NPC1 O15118 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 2/20 0.51
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1124327 1.00 MAPT (0.62) MAPTFOSJUNALDH1A1CYP3A4
Benzene SCHEMBL28260361 0.96 MAPT (0.62) MAPTFOSJUNALDH1A1CYP3A4
SCHEMBL10521756 0.94 MAPT (0.56) MAPTFOSJUNALDH1A1CYP3A4
SCHEMBL13067872 0.94 MAPT (0.56) MAPTFOSJUNALDH1A1CYP3A4
SCHEMBL9864946 0.89 MAOB (0.54) MAPTFOSJUNALDH1A1CYP3A4
SCHEMBL1450230 0.89 F3 (0.52) MAPTALDH1A1MAOBSMN1; SMN2LMNA
SCHEMBL5598702 0.82 JUN (0.74) MAPTFOSJUNALDH1A1CYP3A4
SCHEMBL5598705 0.82 JUN (0.74) MAPTFOSJUNALDH1A1CYP3A4
SCHEMBL22029402 0.80 GLA (0.65) MAPTFOSJUNALDH1A1CYP3A4
SCHEMBL22114228 0.80 MAPT (0.53) MAPTFOSJUNALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US claimed
EP-2282996-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS Actelion Pharmaceuticals Ltd. (CH) 2011-02-16 EP claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
WO-2009141782-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2009-11-26 WO claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
EP-1940814-A1 PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS Actelion Pharmaceuticals Ltd. (CH) 2008-07-09 EP claimed
WO-2007046075-A1 PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2007-04-26 WO claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO claimed
US-12618000-B2 Friction reduction of acidic treatment fluids HALLIBURTON ENERGY SERVICES, INC. (US) 2026-05-05 US disclosed
WO-2025088969-A1 COMPOSITION FOR FORMING CURED FILM, CURED FILM, ALIGNMENT MATERIAL, AND RETARDATION MATERIAL 日産化学株式会社 2025-05-01 WO disclosed
US-12247165-B2 Anti-syneresis agents for fracturing operations HALLIBURTON ENERGY SERVICES, INC. (US) 2025-03-11 US disclosed
US-20250075122-A1 ADDITIVES TO PREVENT THERMAL THINNING IN POLYMER GEL SYSTEMS HALLIBURTON ENERGY SERVICES, INC. (US) 2025-03-06 US disclosed
US-RE36625-E Linear and cyclic polymers or oligomers having a photoreactive ethene group ROLIC AG (CH) 2000-03-21 US disclosed
CN-1049224-C Polymers as alignment layer ROLIC AG (CH) 2000-02-09 CN disclosed
US-5539074-A LIQUID CRYSTAL POLYMERS ON SILICA FOR LIGHT SENSITIVE ELEMENTS HOFFMANN-LA ROCHE INC. (US) 1996-07-23 US disclosed
CN-1091458-A Polymkeric substance as oriented layer HOFFMANN LA ROCHE (CH) 1994-08-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 MAPT 2121/4885FOS 4211/4885JUN 3575/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 MAPT 2121/4885FOS 4211/4885JUN 3575/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 MAPT 2121/4885FOS 4211/4885JUN 3575/4885
US-12618000-B2 Friction reduction of acidic treatment fluids GFER, FGB, NSF MAPT 3558/4885FOS 1670/4885JUN 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.